Zest Health announces $13M in seed funding

Zest Health announced $13M in seed funding. The company said, “Zest Health’s platform provides personalized dermatology care that minimizes unnecessary pharmaceutical utilization while producing sustainable clinical outcomes. The roughly 40 million Americans with eczema and psoriasis face average wait times of over a month and rushed visits as dermatologists increasingly turn to cash-pay models that prioritize aesthetics. To minimize and expedite office visits, prescribers rely on systemic medications to quickly achieve clear skin. Overreliance on these medications has led to rapid growth in associated spend. Biologics for these conditions are being used earlier and more chronically, growing at 15% annually and driving over $40B in annual US spend. Zest provides patients with more personalized, responsive care. Zest’s virtual, high-touch approach is bolstered by patient data to identify optimal prescription regimens, over-the-counter medications, lifestyle changes, and preventative interventions for more convenient, durable relief.” Roivant Health incubated and made this investment in Zest. The funds will be used to scale Zest’s existing partnerships with health plans and employers seeking to address this growing cost pool.